Introduction and objective:
Hepatitis A Virus (HAV), reportedly the most common cause of acute viral hepatitis in developing countries, infects millions of people worldwide each year. The aim of the study is to investigate the seropositivity of anti-hepatitis A virus (HAV) IgG and IgM in all age groups in Erzurum, and to determine the effect of various factors such as age, gender, climatic conditions and HAV vaccination (included in 2012 in the National Immunization Schedule on seroprevalence) on the seropositivity.

Material and methods:
The serological results of 25,007 individuals referred to Erzurum Public Health Microbiology Laboratory between January 2015 – December 2018 were retrospectively reviewed to test for the presence of anti-HAV IgG and IgM. The patient ages were 0–93 years. Serum samples were analyzed by ELISA. S/CO values of ≥1.00 and >1.21 were considered positive for anti-HAV IgG and IgM, respectively; results below this value were considered negative.

Anti-HAV IgG and IgM seropositivities were 87.3% and 0.2%, respectively. Anti-HAV IgG prevalence – 88.5% and 86.4%, anti-HAV IgM positivity – 0.1% and 0.3% in men and women. Anti-HAV IgG seroprevalence – 87%, 73.2%, 58.7%, 75.2%, 86.1%, 89.8%, 96.1%, 99.1%, 99.1% and 99.3%, respectively, at 0–4, 5–9 10–14, 15–19, 20–24, 25–29, 30–39, 40–49, 50–59 and >60 age groups. Anti-HAV IgM seropositivity – 0, 0.1%, 0.7%, 0.7%, 0.3%, 0, 0.1%, 0.2%, 0.1%, and 0.2%, respectively, in the same age groups. Anti-HAV IgM positivity was the highest in November – 36(0.97%.

In Erzurum, anti-HAV IgG prevalence is tremendously high, whereas prevalence of anti-HAV IgM is exceptionally low, especially in the paediatric age group. Therefore, HAV vaccine is provided free of charge in Turkey, including Erzurum, since 2012.

Yis R, Degirmencİ S. Evaluation of Serologic Markers of Viral Hepatitis Due to a Hepatitis A Virus Outbreak Following an Acute Hepatitis A Infection in a Child in the Gaziantep Orphanages. Turkiye Klinikleri J Med Sci. 2013; 33(1): 110–115. doi: 10.5336/medsci.2012-29031.
Melhem NM, Jaffa M, Zaatari M, Awada H, Salibi NE, Ramia S. The changing pattern of hepatitis A in Lebanese adults. Int J Infect Dis. 2015; 30: 87–90.
Franco E, Meleleo C, Serino L, Sorbara D, Zaratti L. Hepatitis A: Epidemiology and prevention in developing countries. World J Hepatol. 2012; 4(3): 68–73. doi: 10.4254/wjh.v4.i3.68.
Jacobsen KH, Wiersma ST. Hepatitis A virus seroprevalence by age and world region, 1990 and 2005. Vaccine. 2010; 28(41): 6653–6657.
Ozaras R, Arends JE. Viral Hepatitis: Acute Hepatitis. Turse EP, Rassow B, Tahan V, editors. Cham, Switzerland: Springer Nature Switzerland AG; 2019. p. 17–24.
Jacobsen KH, Koopman JS. The effects of socioeconomic development on worldwide hepatitis A virus seroprevalence patterns. Int J Epidemiol. 2005; 34(3): 600–609.
Taylor RM, Davern T, Munoz S, Han SH, McGuire B, Larson AM, et al. Fulminant hepatitis A virus infection in the United States: Incidence, prognosis, and outcomes. Hepatology. 2006; 44(6): 1589–1597. ht t ps://
Cuthbert JA. Hepatitis A: old and new. Clin Microbiol Rev. 2001; 14(1): 38–58.
Kurkela S, Pebody R, Kafatos G, Andrews N, Barbara C, Bruzzone B, et al. Comparative hepatitis A seroepidemiology in 10 European countries. Epidemiol Infect. 2012; 140(12): 2172–2181.
Koroglu M, Jacobsen KH, Demiray T, Ozbek A, Erkorkmaz U, Altindis M. Socioeconomic indicators are strong predictors of hepatitis A seroprevalence rates in the Middle East and North Africa. J Infect Public Health. 2017; 10(5): 513–517.
Parlak M. Distribution of anti-HAV IgM positivity according to age and months of a year in Van region, Turkey. Dicle Med J. 2012; 39(3): 398–402. doi: 10.5798/diclemedj.0921.2012.03.0165.
Word Health Organization (WHO). The global prevalence of hepatitis A virus infection and susceptibility: a systematic review: Geneva: World Health Organization; 2010 Contract No.: Document Number|. WHO/IVB/10.01.
Aggarwal R, Goel A. Hepatitis A: epidemiology in resource-poor countries. Curr Opin Infect Dis. 2015; 28(5): 488–496. doi: 10.1097/QCO.0000000000000188.
Yoldaş Ö, Bulut A, Altındiş M. The Current Approach of Hepatitis A Infections. Viral Hepat J. 2012; 18(3): 81–86. doi: 10.4274/Vhd.35744.
Ceyhan M, Yildirim I, Kurt N, Uysal G, Dikici B, Ecevit C, et al. Differences in hepatitis A seroprevalence among geographical regions in Turkey: a need for regional vaccination recommendations. Viral Hepat J. 2008; 15(2): 69–72. ht t ps:// /10.1111/j.1365-2893.20 08.01034.x.
Karaayak Uzun B, Hakan Er H, Gungor S, Pektas B, Baran N, Gul Yurtsever S, et al. Seroprevalence of Hepatitis A and Hepatitis E in Adults Patient Admitted İzmir Katip Çelebi Universty Atatürk Training and Research Hospital. Viral Hepat J. 2013; 19(2): 76–79. doi: 10.4274/Vhd.99608.
Vancelik S, Guraksin A, Alp H. Hepatitis A seroepidemiology in Eastern Turkey. East Afr Med J. 2006; 83(2): 86–90.
Alhan E, Kozanoglu B, Tumgor G, Celik U, Yaman A, Bozdemir N. Epidemiological shift of hepatitis A in central Adana, Turkey. Turk J Gastroenterol. 2014; 25(1): 6–8. doi: 10.5152/tjg.2014.4163.
Ceran N, Yuksel Kocdogan F, Mert D, Erdem I, Dede B, Adaleti R, et al. Hepatitis A seroprevalence in children and young adults in Istanbul, Turkey: seroprevalence change and associated factors. Viral Hepat J. 2012; 19(1): 72–76. ht t ps:// /10.1111/j.1365-2893.2011.01454.x.
Dede A, Clıskan E, Biten Guven G, Cizmeci Z. Hepatitis a Seropositivity in Outpatients at Keçiören Teaching and Research Hospital. Viral Hepat J. 2013; 19(3): 163–164. doi: 10.4274/Vhd.44154.
Bawazir AA, Hart CA, Sallam TA, Parry CM, Beeching NJ, Cuevas LE. Seroepidemiology of hepatitis A and hepatitis E viruses in Aden, Yemen. Trans R SocTrop Med Hyg. 2010; 104(12): 801–805. ht t ps://
Hayajneh WA, Balbeesi A, Faouri S. Hepatitis A virus age-specific sero-prevalence and risk factors among Jordanian children. J Med Virol. 2015; 87(4): 569–574.
Turky A, Akram W, Al-Naaimi A, Omer AR, Rasheed Al-Rawi J. Analysis of Acute Viral Hepatitis (A and E) in Iraq. Glob J Health Sci. 2011; 3(1): 70. doi: 10.5539/gjhs.v3n1p70.
Hoseini SG, Kelishadi R, Ataei B, Yaran M, Motlagh ME, Ardalan G, et al. Seroprevalence of hepatitis A in Iranian adolescents: is it time to introduce a vaccine? Epidemiol Infect. 2016; 144(2): 291–6. ht t ps://
Lee A, Lim HS, Nam CM, Song SM, Yoon HR, Lee KR. [An epidemiological analysis of hepatitis A virus serologic markers during the recent four years in Korea]. Korean J Lab Med. 2009; 29(6): 563–569.
Dominguez A, Bruguera M, Plans P, Espunes J, Costa J, Plasencia A, et al. Declining hepatitis A seroprevalence in adults in Catalonia (Spain): a population-based study. BMC Infect Dis. 2007; 7(1): 73.
Kiyohara T, Sato T, Totsuka A, Miyamura T, Ito T, Yoneyama T. Shifting seroepidemiology of hepatitis A in Japan, 1973–2003. Microbiol Immunol. 2007; 51(2): 185–191. ht tps:// /10.1111/j.1348- 0421.20 07.tb03900.x.
Kalem F, Erayman B, YÜKsekkaya Ş, Kara F. The Seroepidemiology of Hepatitis A in Konya. Viral Hepat J. 2013; 19(1): 19–22. doi: 10.4274/Vhd.29392.
Garcia-Juarez I, Solórzano Santos F, Álvarez MT, Vazquez-Rosales JG. Is there a shift in the epidemiology of hepatitis A in Mexican children? Rev Invest Clin. 2008; 60(4): 292–296.
Turkiye Republic Health Ministry. Available from: 20-03-01).
Kanra G, Tezcan S, Badur S, Turkish National Study T. Hepatitis A seroprevalence in a random sample of the Turkish population by simultaneous EPI cluster and comparison with surveys in Turkey. Turk J Pediatr. 2002; 44(3): 204–210.
Cortes-Martins H, Matos R, Moura S, Almeida L, Ferreira S, Manita C, et al. Anti-HAV IgG seroprevalence in Lisbon region residents: Preliminary results from the National Serological Survey 2015–2016. J Clin Virol. 2016; 82: 79–80. doi: 10.1016/j.jcv.2016.08.158.
Vilibic-Cavlek T, Kucinar J, Ljubin-Sternak S, Kolaric B. Seroepidemio-logy of hepatitis a in the croatian population. Hepat Mon. 2011; 11(12): 997–999. doi: 10.5812/kowsar.1735143X.756.
Thomas HC. Viral Hepatitis. Cowie B, Locarnini SA, editors. UK: John Wiley & Sons Ltd.; 2014. p. 47.
Journals System - logo
Scroll to top